210 related articles for article (PubMed ID: 6460241)
1. Heparin is unable to prevent contact activation by three different membranes.
Stratta P; Canavese C; Mangiarotti G; Pacitti A; Tetta C; Coppo R; Ragni R; Vercellone A
Proc Eur Dial Transplant Assoc; 1981; 18():269-74. PubMed ID: 6460241
[TBL] [Abstract][Full Text] [Related]
2. Objective assessment of heparin requirements for hemodialysis in humans.
Ireland H; Lane DA; Curtis JR
J Lab Clin Med; 1984 Apr; 103(4):643-52. PubMed ID: 6230409
[TBL] [Abstract][Full Text] [Related]
3. The influence of dialyzer geometry on blood coagulation and biocompatibility.
Lins LE; Boberg U; Jacobson SH; Kjellstrand C; Ljungberg B; Skröder R
Clin Nephrol; 1993 Nov; 40(5):281-5. PubMed ID: 8281717
[TBL] [Abstract][Full Text] [Related]
4. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.
Wachtfogel YT; Kucich U; Hack CE; Gluszko P; Niewiarowski S; Colman RW; Edmunds LH
J Thorac Cardiovasc Surg; 1993 Jul; 106(1):1-9; discussion 9-10. PubMed ID: 7686593
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulation and platelet activation in hemodialysis: clinical results with PMMA.
Coli L; Cianciolo G; Feliciangeli G; De Sanctis LB; Zanchelli F; Dalmastri V; De Pascalis A; Sestigiani E; Donati G; Stefoni S
Contrib Nephrol; 1999; 125():111-9. PubMed ID: 9895435
[No Abstract] [Full Text] [Related]
6. Leucopenia, hypoxia and complement activation in haemodialysis. Three unrelated phenomena.
de Vinuesa SG; Resano M; Luño J; Gonzalez C; Barril G; Junco E; Valderrabano F
Proc Eur Dial Transplant Assoc; 1983; 19():159-67. PubMed ID: 6878230
[TBL] [Abstract][Full Text] [Related]
7. Platelet factor release following heparin administration and during extracorporeal circulation.
Flicker W; Milthorpe BK; Schindhelm K; Odell RA; McPherson J; Farrell PC
Trans Am Soc Artif Intern Organs; 1982; 28():431-6. PubMed ID: 6219490
[No Abstract] [Full Text] [Related]
8. Thromboxane B2 blood levels and incipient system clotting in heparin free hemodialysis.
Keller F; Hericks K; Schuller I; Passfall J; Joerres A; Meinhold H
ASAIO J; 1995; 41(2):173-7. PubMed ID: 7640422
[TBL] [Abstract][Full Text] [Related]
9. Intradialytic and postdialytic platelet activation, increased platelet phosphatidylserine exposure and ultrastructural changes in platelets in children with chronic uremia.
Elshamaa MF; Elghoroury EA; Helmy A
Blood Coagul Fibrinolysis; 2009 Jun; 20(4):230-9. PubMed ID: 19521197
[TBL] [Abstract][Full Text] [Related]
10. [Criteria of the biocompatibility of the membranes used in dialysis].
Stratta P; Canavese C; Segoloni GP; Dogliani M; Racca M; Coppo R; Vercellone A
Minerva Nefrol; 1981; 28(2):109-11. PubMed ID: 6457263
[No Abstract] [Full Text] [Related]
11. [Comparison of biocompatibility of hemophane, cellulose diacetate and acrilonitile membranes in hemodialysis].
Germin Petrović D
Acta Med Croatica; 2004; 58(1):31-6. PubMed ID: 15125391
[TBL] [Abstract][Full Text] [Related]
12. Effect of ticlopidine on coagulation and platelet functions during hemodialysis with cuprophan membranes.
Grekas D; Syrganis C; Romtsou S; Makris P; Tsakiris DA; Tourkantonis A
Life Support Syst; 1985; 3 Suppl 1():409-13. PubMed ID: 2959822
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of erythropoietin treatment on the coagulation system during standardized hemodialysis.
Clyne N; Lins LE; Egberg N
Clin Nephrol; 1995 Apr; 43(4):260-7. PubMed ID: 7606881
[TBL] [Abstract][Full Text] [Related]
14. Platelet activation in response to phlebotomy. An experimental study of healthy blood donors.
Eriksson KA; Sigvaldason A; Lindholm A; Safai-Kutti S; Kutti J
Acta Med Scand; 1982; 212(3):121-3. PubMed ID: 6183925
[TBL] [Abstract][Full Text] [Related]
15. [Changes in platelet function in patients with arterial hypertension].
Malý J; Pecka M; Pintérová E; Pidrman V; Bláha M; Siroký O; Jebavý L
Vnitr Lek; 1995 Jul; 41(7):458-61. PubMed ID: 7571480
[TBL] [Abstract][Full Text] [Related]
16. Activation of platelets in patients with chronic proliferative glomerulonephritis and the nephrotic syndrome.
Tomura S; Ida T; Kuriyama R; Chida Y; Takeuchi J; Motomiya T; Yamazaki H
Clin Nephrol; 1982 Jan; 17(1):24-30. PubMed ID: 6459902
[TBL] [Abstract][Full Text] [Related]
17. Activation of blood platelets in chronic hepatitis and liver cirrhosis P-selectin expression on blood platelets and secretory activity of beta-thromboglobulin and platelet factor-4.
Panasiuk A; Prokopowicz D; Zak J; Matowicka-Karna J; Osada J; Wysocka J
Hepatogastroenterology; 2001; 48(39):818-22. PubMed ID: 11462931
[TBL] [Abstract][Full Text] [Related]
18. Platelet and leucocyte behaviour during haemodialysis.
Hoenich NA
Contrib Nephrol; 1999; 125():120-32. PubMed ID: 9895436
[No Abstract] [Full Text] [Related]
19. Platelet compatibility of an artificial surface modified with functionally active heparin.
Mollnes TE; Videm V; Christiansen D; Bergseth G; Riesenfeld J; Hovig T
Thromb Haemost; 1999 Sep; 82(3):1132-6. PubMed ID: 10494777
[TBL] [Abstract][Full Text] [Related]
20. Increased activation of the coagulation and fibrinolytic systems leads to hemorrhagic complications during left ventricular assist implantation.
Livingston ER; Fisher CA; Bibidakis EJ; Pathak AS; Todd BA; Furukawa S; McClurken JB; Addonizio VP; Jeevanandam V
Circulation; 1996 Nov; 94(9 Suppl):II227-34. PubMed ID: 8901751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
